Related references
Note: Only part of the references are listed.Impact of different HER2 expression levels on the outcomes of second-line immunotherapy for metastatic urothelial carcinoma.
Siming Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).
Matt D. Galsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives
Giorgio Patelli et al.
CANCER TREATMENT REVIEWS (2022)
Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy
Fan Shi et al.
DRUG DELIVERY (2022)
A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma.
Huayan Xu et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Yelena Y. Janjigian et al.
NATURE (2021)
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study
Zhi Peng et al.
CANCER COMMUNICATIONS (2021)
RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib/II study.
Li Zhou et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009).
Xinan Sheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Xinan Sheng et al.
CLINICAL CANCER RESEARCH (2021)
Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC).
Sun Young Rha et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The emerging role of antibody-drug conjugates in urothelial carcinoma
Michael Lattanzi et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2020)
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
Sherene Loi et al.
LANCET ONCOLOGY (2019)
HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
Tiziana Triulzi et al.
ONCOIMMUNOLOGY (2019)
Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN gamma secretion
Bharat K. R. Chaganty et al.
CANCER LETTERS (2018)
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer
Thomas Powles et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V. Balar et al.
LANCET ONCOLOGY (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Antibody-drug conjugates-an emerging class of cancer treatment
Nikolaos Diamantis et al.
BRITISH JOURNAL OF CANCER (2016)
Quantitative characterization of in vitro bystander effect of antibody-drug conjugates
Aman P. Singh et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2016)
Multicentre randomised phase II trial of gemcitabine plus platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2
Stephane Oudard et al.
EUROPEAN JOURNAL OF CANCER (2015)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer (vol 17, pg v118, 2006)
Hans von der Maase et al.
ANNALS OF ONCOLOGY (2011)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium:: Results of a randomized phase 2 trial
Luigi Dogliotti et al.
EUROPEAN UROLOGY (2007)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
